SKBA Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
SKBA Capital Management's REGN Position: Q2 2026 in Review
SKBA Capital Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 1,295 shares worth $807K. The position accounts for 0.13% of the portfolio, ranked #64.
SKBA Capital Management first reported a position in REGN in Q4 2019 and has held it in 27 quarters since. The position peaked at $1M in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- SKBA Capital Management held 1,295 shares of Regeneron Pharmaceuticals worth $807K as of Q2 2026.
- SKBA Capital Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
- Regeneron Pharmaceuticals made up 0.13% of SKBA Capital Management's portfolio in Q2 2026, its #64 holding.
- SKBA Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
- SKBA Capital Management's Regeneron Pharmaceuticals position peaked at $1M in Q1 2026.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on SKBA Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.